Society for Neuroscience - 39th Annual Meeting. Part 2 - Novel therapies for neurodegenerative disorders and other CNS diseases.
The 39th Annual Meeting of the Society for Neuroscience (SFN), held in Chicago, included topics covering new therapeutic developments in the field of neuroscience. This conference report highlights selected presentations on novel neuroprotective and antiparkinsonian agents, and compounds in development for the treatment of dementia, schizophrenia, depression, obesity and spinal muscular atrophy. Investigational drugs discussed include velusetrag and TD-8954 (both from Theravance Inc), SEP-228791 and SEP-226330 (both from Sepracor Inc), ADL-5510 (Adolor Corp), PF-217830 (Pfizer Inc), KB-099520 (Karo Bio AB), tesofensine (NeuroSearch A/S) and TRP6-01 (Theraptosis).
Al-Shamahi
Asma
A
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. asma.al-shamahi@thomsonreuters.com
Kirkham
Konrad
K
Hookes
Livia
L
D000818:Animals; D002491:Central Nervous System Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000503:physiopathology
D002491:Central Nervous System Agents; D015507:Drugs, Investigational